SAB Biotherapeutics Investor Relations Material
Latest events
Q2 2025
7 Aug, 2025
Q1 2025
8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from SAB Biotherapeutics Inc
Access all reports
SAB Biotherapeutics Inc. is a biotechnology company focused on developing immunotherapies using its proprietary DiversitAb platform. The company specializes in producing targeted, fully human polyclonal antibodies for infectious diseases, autoimmune disorders, and other conditions. SAB Biotherapeutics leverages genetically engineered cattle to generate scalable and high-potency antibody treatments. The company is headquartered in Sioux Falls, South Dakota, and its shares are listed on the NASDAQ.
Key slides for SAB Biotherapeutics Inc
Corporate Presentation
SAB Biotherapeutics Inc
Study Update
SAB Biotherapeutics Inc
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
SABS
Country
🇺🇸 United States